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ABSTRACT

Compounds belonging to novel classes of 2-oxo-1,4benzoxazine heterocyclic compounds and their close
derivatives, are disclosed along with the surprising use
property of these compounds as bacteriostatic agents for
humans and non-humans against mycobacteria. These species include: 4-benzoyl-3-benzoyloxy-2-(2-oxo-2H-1,4benzoxazin-3-yl)pyrido[2,l-c ][1,4 ]benzoxazin-1,5-dione;
and, 2,4,6-trimethylphenyl 2-(3,4-dihydro-2-oxo-2H-1,4b e nzo x azin -3-y lidene )-3-p-me thoxypheny 1-3-oxopropanoate.
7 Claims, 1 Drawing Sheet
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drug supply. The failure of patients to complete therapy as
well as inappropriate monotherapy has led to the emergence
and distribution of strains of Mycobacterium tuberculosis
resistant to every available chemotherapy (Bloom B R and
This application claims the benefit of priority of U.S.
Provisional Application Serial No. 60/292,985 filed May 23, 5 Murray C J L, Science (1992) 257, 1055-1064). Such
organisms will not remain confined to the Third World or to
2001.
the poor and indigent of developed countries. The recent
FIELD OF THE INVENTION
documentation of the spread of a single clone of multi-drugresistant Mycobacterium tuberculosis (the "W" strain)
This invention relates to novel 2-oxo-1,4-benzoxazine
10 throughout the continental United States and Europe highheterocyclics and more particularly to certain novel comlights the danger of an airborne pathogen in our global
pounds and their close derivatives and to the use of these
society (Bifani P J, et al., JAMA (1996) 275, 452-457).
compounds as a bacteriostatic agent (a chemical agent that
The patent literature has numerous accounts of benzoxstops or inhibits the multiplication of bacteria) for human
azine heterocyclics including:
and non-humans against Mycobacterium tuberculosis.
15
Frechette (U.S. Pat. No. 5,696,117), Frechette (U.S. Pat.
BACKGROUND OF THE INVENTION
No. 5,854,242) and Frechette (U.S. Pat. No. 5,707,990)
describe
148 benzoxazine and pyrido-oxazine heteroThe infectious disease, tuberculosis (TB), is the leading
cyyclic as anti-bacterial compounds;
cause of death worldwide from a single human pathogen,
Omedi-Sale (U.S. Pat. No. 3,862,954) shows tri-azole
claiming more adult lives than diseases such as acquired 20
compounds for CNS use;
immunodeficiency syndrome (AIDS), malaria, diarrhea, leprosy and all other tropical diseases combined (Zumla A,
Hawkins (U.S. Pat. No. 5,274,002) describes many anaGrange J. B M J (1998) 316, 1962-1964). The organism
logs of phenyl ethers of a substituted phenyl of the
usually responsible is the tubercle bacillus, Mycobacterium
formula structure at column 1, lines 49-60 with 37
tuberculosis (MT), discovered by Robert Koch in 1882. 25
examples of specific compounds which compounds
However, M. bovis, which infects cattle may also infect man
may be useful for tumor inhibition (column 22, line
and M. africanum is a cause of TB in West Africa.
64); and,
Furthermore, a number of normally non-pathogenic
Boyd, et al (U.S. Pat. No. 6,080,790) also describes many
mycobacteria, especially M. avium, M. intracellulare and M.
tri-substituted phenyl derivatives according to the forscrofulaceum, cause opportunistic infectious disease in 30
mula of the Abstract with 15 examples of specific
patients with AIDS (Horne N. 1996. Tuberculosis and other
compounds which may be useful for malignant skin
mycobacteria diseases. In Mansons Tropical Diseases, 20'h
diseases (column 5, line 46).
edn, Cook FEG (ed). W B Saunders: London; 971-1015).
For half a century, the most used antimicrobial agents
Pulmonary TB, the most common type of the disease, is
referenced above for prophylaxis and treatment of tubercuusually acquired by inhalation of the bacillus from an 35 losis since 1952 is isoniazid (isonicotinic acid hydrazide
infectious patient and causes irreversible lung destruction.
[INH]). One of the known complications of anti-tuberculosis
About one third of the world's population is currently
chemotherapy caused by this drug is liver dysfunction plus
infected with M. tuberculosis; 10% of those infected will
a great number of other complications. The toxicity of INH
develop clinical diseases, particularly those who also have
is also a serious problem frequently resulting in poisoning.
the human immunodeficiency virus (HIV) infection (Zumla 40 It is also known to be an acute/chronic hazards since INH is
A, Grange J. B M J (1998) 316, 1962-1964). With the
an irritant of the skin, eyes, mucous membranes and upper
discovery of effective anti-mycobacterial agents (including
respiratory tract.
ethambutol, isoniazid, pyrazinamide, rifampicin and
It appears from a review of the above that the benzoxazine
streptomycin) and a reduction in poverty, there was a drastic
heterocyclic compounds of interest are not disclosed nor is
decline in the number of TB cases, especially in developed 45 there any report of activity against Mycobacterium tubernations. However, since the late 1980s, the number of cases
culosis or related mycobacteria.
of TB throughout the world has been increasing rapidly
Consequently, there is a need for an anti-mycobacteria
partly due to the emergence of multi-drug resistant M.
drug for humans and non-humans which mitigates the above
tuberculosis (C. E. Barry, III, Biochemical Pharmacology
mentioned disadvantages of current drug bacteriostatic
(1997) 54, 1165-1172). According to the World Health 50 agent effectiveness against human and non-human mycoOrganization (World Health Organization. 1993 92. per
bacteria.
Besra GS, Brennan P J. 1997. J Pharm Pharmacol 49 (Suppl.
SUMMARY OF THE INVENTION
1):25-30.s), it is expected that the annual death rate caused
by TB will reach an overwhelming 3.5 million by the year
The first objective of the present invention is to provide a
2000.
55
bacteriostatic agent this is effective against mycobacteria.
Thus the TB problem requires urgent attention. Short
The second object of this invention is to provide a
course anti-TB regiments initially using at least three firstbacteriostatic agent that is effective in human and nonline drugs (including isoniazid, rifampicin and
humans against mycobacteria.
pyrazinamide) are often not effective due to an increase in
A third object of this invention is to provide a bacteriothe number of tuberculosis strains that have become resistant 60
static
agent that is effective in human and non-humans
to current drugs. For example the World Health Organization
against Mycobacterium tuberculosis.
(WHO) recently reported that the death rate of patients with
A further object of this invention is to provide novel
multi-drug resistant (MDR) tuberculosis in the US was
2-oxo-1,4-benzoxazine heterocyclics.
approximately 70%. Current treatment is also very expenA preferred embodiment of the invention encompasses a
sive: a 3 drugs regimen is needed (more than $500/month 65
class of heterocyclics having the property of bacteriostatic
cost per patient). Thus the major problems faced in tuberculosis control are poor infrastructures for diagnosis and
agent activity against Mycobacterium tuberculosis compris-
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ing 2-oxo-1,4-benzoxazine heterocyclics and more specifically those heterocyclics: 4-benzoyl-3-benzoyloxy-2-(2oxo-2H-1,4-benzoxazin-3-yl)pyrido[2,l-c ][1,4 ]benzoxazin1,5-dione; and, 2,4,6-trimethylphenyl 2-(3,4-dihydro-2-oxo2H-1,4-benzoxazin-3-ylidene)-3-p-methoxyphenyl-3-oxopropanoate and the use of each in human and non-humans as
therapeutic means for the eradication of Mycobacterium
tuberculosis.
Further objects and advantages of this invention will be
apparent from the following detailed description of presently
preferred embodiments which are illustrated structurally in
the accompanying drawings.

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile; somewhat soluble in ethanol,
tetrachloromethane; and, insoluble in hexane and water.
5

PREPARATION OF lF-18
EXAMPLE 1

The preparation of 4-benzoyl-3-benzoyloxy-2-(2-oxo2H-1,4-benzoxazin-3-yl)pyrido[2,l-c ][1,4 ]benzoxazin-1,510 dione (lF-18).
A solution of 1.5 g (0.047 moles) of compound 4 in 10 mL
of dowtherm A * * was kept at constant temperature at
183-186° C. for 30 min. The solution was cooled and the
BRIEF DESCRIPTION OF THE FIGURES
resulting precipitate of lF-18 was filtered and recrystallized
FIG. 1 illustrates structurally a chemical compound des- 15 from acetonitrile to give 0.79 g (54%) of orange crystals
with mp of 259-261° C. (decomposes).
ignated as lF-18.
The following reactions are illustrative of the synthesis of
FIG. 2 illustrates structurally a chemical compound des(lF-18)
ignated as lF-19.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS

Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the
particular arrangement shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The general class of 2-oxo-1,4-benzoxazine heterocyclics
is more fully illustrated by those compounds having the
structure:

20

25

2

30

oc:x:_COCJC,
35

I

I

H

H
3

-co

40

45

R 1 =H or CH 3
R2 =aryl
More specifically this application is for the antituberculosis compounds lF-18 and lF-19, which have been
structurally shown in FIGS. 1 and 2, respectively. Compound lF-18 surprisingly has also demonstrated 100% activity against human and non-human myeloma.
To facilitate a full understanding of the invention: the
compound designated as lF-18 is 4-benzoyl-3-benzoyloxy2-(2-oxo-2H-1,4-benzoxazin-3-y l)pyrido[2,l-c ][1,4]
benzoxazin-1,5-dione; and, the compound designated as
lF-19 is 2,4,6-trimethylphenyl 2-(3,4-dihydro-2-oxo-2H-1,
4-benzoxazin-3-y lidene )-3-p-methoxypheny 1-3-oxopropanoate.
These compounds are highly active against Mycobacterium tuberculosis and have a very low toxicity, a lethal dose
50 (LD 50 ) in animals. The percent activity and animal
toxicity for each compound is as follows: lF-18 (95% and
LD 50 >2000 mg/kg), and lF-19 (97% and LD 50 >1000
mg/kg).

0

50
0
0

ox)
N

55

lF-18
60

65

R = Hor Alk(CH3, C2Hs)
**Content: 73.5% phenyl ether
26.5% diphenyl

Described in L. Fieser, M. Fieser, Reagents for Organic
Synthesis, Wiley, New York, 1968.
A detailed synthesis of compound 4 has been published
earlier in: Five-membered-ring 2,3-dioxoheterocycles.
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XXXIII. Synthesis of 3-aroyl-l,2-dihydro-4H-pyrrolo[5,1c ][1,4]benzoxazine-l,2,4-triones and their reaction with
water and alcohols. Mashivets, A N.; Mashevskaya, I. V.;
Krasnykh, 0. P.; Shurov, S. N.; Andreichikov, V. S. Perm.
Gos. Univ., Perm, Russia. Zh. Org. Khim. (1992), 28(12),
2545-53. CODEN: ZORKAE ISSN: 0514-7492 and the
synthesis of compound 3 was previously published by
Iwanami Y., Seki T., Inagaki T., Bull. Chem. Soc. Jpn., 1971,
44, 1316. and Iwanami Y., Inagaki T., J. Heterocycl. Chem.,
1976, 13(4), 681-684.

-continued

R=H,OH;

Moo

5

H3C

10

PREPARATION OF lF-19
EXAMPLE 2

15

The preparation of 2,4,6-trimethylphenyl 2-(3,4-dihydro2-oxo-2H-1,4-benzoxazin-3-ylidene)-3-p-methoxypheny 13-oxo-propanoate (lF-19). A solution of 0.5 g (0.0014
moles) of compound 4' and 0.38 g (0.0028 moles) of
2,4,6-trimethylphenol in 10 ml of absolute pseudocumene
was refluxed for 20 min, cooled and the resulting precipitate
of lF-19 was filtered and recrystallized from phenol to give
0.52 g (80%) of yellow crystals with mp of 224-227° C.
Solubility: The compound is highly soluble in in DMSO,
DMFA, acetonitrile, dichloroethane; somewhat soluble in
phenol, tetrachloromethane; and, insoluble in hexane and
water.
The following reactions are illustrative of the synthesis of
(lF-19)

CH30 - 0 - w - C H = 1 - C O O R
0

+

20

25

30

35

OH

40

(COCl)2
-2HC1

0

-:?'c......._

50

O:l(=o•4=•r•
0

45

C6H40CH3-p

2

l'J., MesOH

-co
55

0
4

60

lF-19
A

--P-rn,
H3C

65

In polar solutions of lF-19 the presence of small amounts of
tautomer is observed.
The bacteriostatic activity against Mycobacterium tuberculosis of the novel compounds (as earlier reported on page
5, lines 9-12) was realized by the following procedure.
BIO-ASSAY PROCEDURE
Compound processing: Synthetic compounds lF-18, and
lF-19 were each first dissolved in 500 ml of dimethylsulfoxide (DMSO) in individual beakers and each placed on a
rotary shaker overnight. Distilled water was added to each to
provide a final concentration of 10 mg/ml. Each solution was
filter-sterilized using Becton Dickinson 5 ml sterile syringes
and Whatman 22 um sterile filters. Each of the filtered
sterilized synthetic test solutions (designated as synthons
hereafter) were stored at -20 degrees centigrade until used.
Culture media and bioassay analytical techniques:
BACTEC 12B Mycobacteria also known as Middlebrook
7H12 Medium was purchased from Becton Dickinson
(Pittsburgh, Pa.). It contains 7H9 broth base, casein
hydrolysate, bovine serum albumin, catalase and palmitic
acid labeled with 14 C. It is specific for growing Mycobacteria and is used in conjunction with the BACTEC brand 460
TB Analyzer. This Middlebrook 7H9 broth base media
consist of 4 ml of broth mixture included in a sealed bottle.
The culture used in the bioassay was M. tuberculosis ATCC
25177. The synthons were added to Bactec 7H12 B+ bottled
liquid media using Becton Dickinson B-D 1 ml sterile
syringes to a final concentration of 0.1 mg/ml. To each of
these Bactec bottles, 100 ul of Bactec 7H12 B+ cultured M.
tuberculosis was inoculated using Becton Dickinson B-D "1
cc" sterile syringes. Microbial growth activity in this culture
medium is indicated by the release of 14C0 2 into the
atmosphere of the sealed vial following the hydrolysis of
14
C-labeled palmitic acid by the microorganism. The
BACTEC 460 TB Analyzer: The gas in the atmosphere of
the sealed BACTEC 12B vial is aspirated from the vial via
a sterile needle attached to a robotic inside the BACTEC 460
TB Analyzer System. The BACTEC Analyzer operates by
initially drawing room air through a dust filter, a flush valve,
and an ion chamber transferring all 14C0 2 into C0 2 trap
where it is retained. This process cleans the electrometer and
leaves it ready to start the next cycle. During the next cycle,
a pair of 18G needles are heated. A pump produces a partial
vacuum in the ion chamber used to lower the testing needles
through the rubber septum of the vial being tested. A vacuum
draws culture gas from the vial to the ion chamber. The
electrometer measures the very small current that the radioactive 14C0 2 produces in the ion chamber. Following
removal of the radioactive culture gas, fresh 5% C0 2 is
introduced into the medium headspace every time a vial is
tested, enhancing the growth of mycobacteria. The current
measured by the electrometer is amplified and displayed as
a growth index (GI). The growth index is measured on a
scale of 0 to 999 and is an indication of microbial growth
activity in the bottle. Usually, a GI of 10 or higher is an
indication of definite microbial growth. The percent growth,
and the percent inhibition in the presence of extract was
calculated by the following formulas:

US 6,649,610 Bl
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%GR=

G/(with no extract)
G/(with the extract)

xl00%

GR:Percent growth, G/:Growth index, /N:Percent inhibition

5

ingestion, inhalation and skin absorption [Leuga, Robert E.
The Sigma-Aldrich Library of Chemical Safety Data. Edition 1. Sigma-Aldrich Corporation. Milwaukee, Wis. 1985.
p. 1114, #A].

Animal Toxicity Bioassay. Acute toxicity was studied on
The acute toxicity of isoniazid is as following: LCLO
white mice of both sexes with weight ranging between
(lowest published lethal concentration) for man is 100
18-26 grams under intraperitoneal injection of 2% solution
mg/kg. In animal testing with white mouse LD 50 (lethal dose
10
of tested compound in starch (the compound was dissolved
50 percent kill) for isoniazid was shown to be 100 mg/kg
in starch slime and injected) on the basis of 0.1 ml of
(the same intraperitoneal injection method (Krasil'nikov, I.
solution per 10 g of the animal weight. Each dose was tested
I.; Parfenov, A I.; Strel'nikov, Yu. E.; Smirnova, S. M.
on the group of 6 animals that were observed during 14 day
Radiobiologiya (1973), 13(4), 551-4), which was used by us
period. (This method was approved by the Pharmacology 15
to determine LD 50 dose). All toxicity information about
committee of Russian Ministry of Health and has been
isoniazid can also be found on the web site: http://ntpwidely used since 1968.) Averaged lethal dose (LD 50 ) of the
server.niehs.nih.gov/htdocs/Chem H&S/NTP Chem5/
compound was computed using results of experiments on
Radian54-85-3.html
5-7 groups of animals using the method of Litchfield and
Wilkinson. (Belenkii M. L. "Elements of quantative deter- 20
mination of the pharmacological effect," Leningrad, 1963,
In addition there are a number of reports in recent
71 pages).
literature which suggest the importance of developing a new
The disclosed invention makes it possible to produce and
treatment to combat strains of the deadly disease,
isolate oxo-heterocyclics, which have the property of bac- 25 tuberculosis, which have become resistant to current drugs.
teriostatic agent activity toward Mycobacterium tuberculosis.
By reference to page 5, lines 9-12 it is seen that all of the
specific
compounds of the invention exhibit at least 10 times
ADVANTAGES OF THE DISCOVERY
30 lower acute toxicity compare to isoniazid and high activity
This discovery has several advantages. In the Background
values.
of the Invention there was a short description of one of the
most used primary anti-mycobacteria agents for prophylaxis
The heterocyclic 2-oxo-1,4-benzoxazine compounds of
and treatment of tuberculosis since 1952. The name of this
drug is isoniazid (isonicotinic acid hydrazide [INH]). 35 the invention which are unique in their anti-tubercular
activity are to be used in a pharmaceutical composition
Patients with a recently positive protein positive derivative
comprising a non-toxic effective amount of the referenced
(PPD) skin test and a normal chest x-ray routinely are given
a 6- to 9-month course of isoniazid. Liver dysfunction is one
heterocyclic compound or a tautomeric form thereof or a
of known complications of anti-tuberculosis chemotherapy
pharmaceutically acceptable salt thereof or pharmaceuticaused by this drug among a great number of other com- 40 cally acceptable solvate thereof, and a pharmaceutically
plications when isoniazid is co-administrated with other
acceptable carrier therefor.
drugs (W.W. Yew, Clinica ChimicaActa 313 (2001) 31-36).
The toxicity issue is also a serious problem. In the US: A
Additional derivatives of the heterocylic 2-oxo-1,4 bensurveillance of cases of isoniazid poisoning by the American 45 zoxazine compounds are hereafter set forth in the following
Association of Poison Control Centers from 1985-1993
table which derivatives conform to the structural formula
revealed a low number of 138 cases in 1985, with no
indicated by:
fatalities, and a high number of 2656 cases in 1991, with 6
fatalities. Mortality/Morbidity: Acute ingestion by adults
with as little as 1.5 g of isoniazid can lead to mild toxicity. 50
Ingestion of 6-10 g may be fatal, while ingestion of 15 g is
usually fatal if not appropriately treated. The overall mortality rate for acute isoniazid toxicity has been estimated to
be 19%. With current methods of supportive care, however, 55
this figure may be high. From 1972-1988, an estimated 152
fatalities were caused by isoniazid-related hepatitis. The
overall hepatitis-related death rates among patients using
isoniazid prophylaxis is approximately 0.001 %. Among
individuals who complete a full course of prophylaxis, the 60
hepatitis-related death rate has been calculated to be
23.2-57.9/100,000. The mortality rate among individuals
who develop overt isoniazid-induced hepatitis is 10%.
Isoniazid is also known to be anacute/chronic hazards. 65
R 1 =H or CH 3
This compound is an irritant of the skin, eyes, mucous
R 2 =aryl
membranes and upper respiratory tract. It can cause harm by
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#

Name

Structure

CC
n,c*rn,
#

3-0xo-2-(2-oxo-4H-benzo[1,4]oxazin-3ylidene)-3-phenyl-propionic acid 2,4,6trimethyl-phenyl ester

N
H

0

0

CH3

2

CC
n,c*rn,
#

3-0xo-2-(2-oxo-4H-benzo[1,4]oxazin-3ylidene)-3-p-tolyl-propionic acid 2,4,6trimethyl-phenyl ester

N
H

0

0

CH3

CH3

3

CC
n,c*rn,
#

3-0xo-2-(2-oxo-4H-benzo[1,4]oxazin-3ylidene)-3-o-tolyl-propionic acid 2,4,6trimethyl-phenyl ester

N
H

0

0

CH3

4

CC
n,c*rn,
#

N
H

0

CH3

0

3-0xo-2-(2-oxo-4H-benzo[1,4]oxazin-3ylidene)-3-m-tolyl-propionic acid 2,4,6trimethyl-phenyl ester
CH3
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-continued

#

5

Name

Structure

cc
#

3-( 4-Ethyl-phenyl)-3-oxo-2-(2-oxo-4Hbenzo[ 1,4]oxazin-3-ylidene)-propionic
acid 2,4,6-trimethyl-phenyl ester

N
H

n,c*rn,
0

cxo
#

0

C2Hs

CH3

3-( 4-Ethoxy-phenyl)-3-oxo-2-(2-oxo-4Hbenzo[ 1,4]oxazin-3-ylidene)-propionic
acid 2,4,6-trimethyl-phenyl ester

N
H

n,c*rn
0

0

OC2Hs

CH3

7

cxo
#

3-(2,5-Dimethyl-phenyl)-3-oxo-2-(2-oxo4H-benzo[ 1,4]oxazin-3-ylidene)propionic acid 2,4,6-trimethyl-phenyl
ester

N
H

n,c*rn,
0

8

CH3

CH3

cxo
#

0

3-(2,4-Dimethyl-phenyl)-3-oxo-2-(2-oxo4H-benzo[ 1,4]oxazin-3-ylidene)propionic acid 2,4,6-trimethyl-phenyl
ester

N
H

n,c*rn,
0

CH3

0

CH3
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-continued

#

9

CC
#

10

Name

Structure

o

3-(3,4-Dimethyl-phenyl)-3-oxo-2-(2-oxo4H-benzo[ 1,4]oxazin-3-ylidene)prop ionic acid 2,4,6-trimethyl-phenyl
ester

N
H

cco
#

3-0xo-2-(2-oxo-4H-benzo[1,4]oxazin-3ylidene)-3-(2,4,6-trimethyl-phenyl)propionic acid 2,4,6-trimethyl-phenyl
CH3

ester

N
H

n,cvcn,
O H3C

11

cco
#

CH3

3-(2,4-Dimethoxy-phenyl)-3-oxo-2-(2oxo-4H-benzo[ 1,4]oxazin-3-ylidene)propionic acid 2,4,6-trimethyl-phenyl
ester

N
H

n,cvcn,
0

12

cco
#

0

OCH3

CH3

3-(3,4-Dimethoxy-phenyl)-3-oxo-2-(2oxo-4H-benzo[ 1,4]oxazin-3-ylidene)propionic acid 2,4,6-trimethyl-phenyl
OCH3

N
H

n,c*cn,
0

CH3

0

OCH3

ester
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-continued

#

Name

Structure

2-( 6-Methyl-2-oxo-4H-benzo[ 1,4]oxazin3-y lidene)-3-oxo-3-phenyl-propionic acid
2,4,6-trimethyl-phenyl ester

13

14

H3C

_cc

2-( 6-Methyl-2-oxo-4H-benzo[ 1,4]oxazin3-y lidene)-3-oxo-3-p-tolyl-propionic acid
2,4,6-trimethyl-phenyl ester

N

H

n,c*rn
0

0

CH3

15

H3C

_cc

2-( 6-Methyl-2-oxo-4H-benzo[ 1,4]oxazin3-y lidene)-3-oxo-3-o-tolyl-propionic acid
2,4,6-trimethyl-phenyl ester

N

H

n,c*rn,
0

0

CH3
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H3C

_cc

2-( 6-Methyl-2-oxo-4H-benzo[ 1,4]oxazin3-y lidene)-3-oxo-3-m-tolyl-propionic
acid 2,4,6-trimethyl-phenyl ester

N

H

n,c*rn
0

CH3

0
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3-( 4-Ethyl-phenyl)-2-( 6-methyl-2-oxo4H-benzo[ 1,4]oxazin-3-ylidene)-3-oxopropionic acid 2,4,6-trimethyl-phenyl
ester

N

H

n,c*cn,
0

0

CH3

18

H3C

3-( 4-Ethoxy-phenyl)-2-( 6-methyl-2-oxo4H-benzo[ 1,4]oxazin-3-ylidene)-3-oxopropionic acid 2,4,6-trimethyl-phenyl

,,(~(

ester

N

H

n,c*cn,
0

0

CH3

19

H3C

3-(2,4-Dimethyl-phenyl)-2-(6-methyl-2oxo-4H-benzo[ 1,4]oxazin-3-ylidene)-3oxo-propionic acid 2,4,6-trimethylphenyl ester

,,(~(

N

H

n,c*rn
0

0

CH3

20

H3C

,,(~(

CH3

N

H

n,c*cn,
0

CH3

0

3-(2,5-Dimethyl-phenyl)-2-(6-methyl-2oxo-4H-benzo[ 1,4]oxazin-3-ylidene)-3oxo-propionic acid 2,4,6-trimethylphenyl ester
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21

CH3

3-(3,4-Dimethyl-phenyl)-2-(6-methyl-2oxo-4H-benzo[ 1,4]oxazin-3-ylidene)-3oxo-propionic acid 2,4,6-trimethylphenyl ester

22

3-(2,4-Dimethoxy-phenyl)-2-(6-methyl2-oxo-4H-benzo[1,4]oxazin-3-ylidene)-3oxo-propionic acid 2,4,6-trimethylphenyl ester

23

3-(3,4-Dimethoxy-phenyl)-2-(6-methyl2-oxo-4H-benzo[1,4]oxazin-3-ylidene)-3oxo-propionic acid 2,4,6-trimethylOCH3 phenyl ester

24

2-( 6-Methyl-2-oxo-4H-benzo[ 1,4]oxazin3-y lidene)-3-oxo-3-(2,4,6-trimethylphenyl)-propionic acid 2,4,6-trimethylphenyl ester

CH3

The invention thus provides a method for the treatment
and/or prophylaxis ofMycobacteria tuberculosis and related
mycobacteria in humans or non-humans. This invention
comprises administering an effective, non-toxic, amount of
a heterocyclic compound according to the invention or a
tautomeric form thereof and/or a pharmaceutically accept-
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able salt thereof and/or a pharmaceutically acceptable solvate thereof, to a tubercular( or mycobacteria infected)
human or non-human in need thereof.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in a mixture with a pharmaceutical carrier selected
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with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution which may contain other
substances, for example enough salts or glucose to make the
solution isotonic.
For administration to man in the curative or prophylactic
treatment of tuberculosis (or other mycobacterium), in vitro
dosages of compounds of the invention will generally be in
the range of from 5 to 500 mg daily for an average adult
patient (70 kg). Thus for a typical adult patient, individual
tablets or capsules contain from 2-500 mg of active
compound, in a suitable pharmaceutically acceptable vehicle
or carrier, for administration in single or multiple doses,
once or several times per day. Dosages for intraveneous,
buccal or sublingual administration will typically be within
the range of from 5-1000 mg per single dose as required. In
practice the physician will determine the actual dosing
regimen which will be most suitable for an individual patient
and it will vary with age, weight and response of the
particular patient. The above dosages are exemplary of the
average case but there can be individual instances in which
higher or lower dosage ranges may be merited, and such are
within the scope of this invention. The maximum non-toxic
one time administration dose for the compound(s) of the
invention appear to be 1000 mg/kg.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capsules or ovules either alone or in admixture with
excipients, on in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution which may contain other
substances, for example enough salts or glucose to make the
solution isotonic with blood.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
1. A class of heterocyclics having the property of bacteriostatic agent activity against mycobacteria comprising

2-oxo-1,4-benzoxazine heterocyclics having the structural
formula indicated by:
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Rl=H or CH 3
R2=aryl.
2. The heterocyclic according to claim 1, which is
4-benzoyl-3-benzoy loxy-2-(2-oxo-2H- l,2-benzoxazin-3-y1)
pyrido[2,l-c ][1,4 ]benzoxazin-1,5-dione.
3. The compound according to claim 1, which is 2,4,6trimethylphenyl 2-(3,4-dihydro-2-oxo-2H-1,4-benzoxazin3-ylidene)3-p-methoxyphenyl-3-oxo-propanoate.
4. A pharmaceutical composition comprising a non-toxic
amount of the compound according to claim 1, or a tautomeric form thereof or a pharmaceutically acceptable salt
thereof or pharmaceutically acceptable solvate thereof, and
a pharmaceutically acceptable carrier therefore.
5. A method for the treatment of Mycobacterium tuberculosis (and other mycobacteria) in a human or non-human
which comprises administering an effective, non-toxic
amount of a compound according to claim 1, or a tautomeric
form thereof and/or pharmaceutically acceptable salt thereof
and/or a pharmaceutically acceptable solvate thereof, to a
tubercular human or non-human in need thereof.
6. A method for the treatment of Mycobacterium tuberculosis and other mycobacteria in a human or non-human
which includes administering to said human or non-human
in need thereof, an effective, non-toxic amount of a compound according to claim 1, or a tautomeric form thereof
and/or pharmaceutically acceptable salt thereof and/or a
pharmaceutically acceptable solvate thereof which compound is 4-benzoyl-3-benzoyloxy-2-(2-oxo-2H-1,4benzoxazin-3-yl)pyrido[2,l-c ][1,4]benzoxazin-1,5-dione.
7. A method for the treatment of Mycobacterium tuberculosis in a human or non-human which includes administering to said human or non-human in need thereof, an
effective, non-toxic amount of a compound according to
claim 1, or a tautomeric form thereof and/or pharmaceutically acceptable salt thereof and/or a pharmaceutically
acceptable solvate thereof which compound is 2.4.6trimethy lpheny1 2-(3,4-dihydro-2-oxo-2H-1,4-benzoxazine3-ylidene)-3-p-methoxypheny1-3-oxo-propanoate.
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